WFRF:(Frisk Karin)
Sökning: WFRF:(Frisk Karin) > (2015-2019) > No association betw...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04457naa a2200493 4500 | |
| 001 | oai:DiVA.org:umu-154049 | |
| 003 | SwePub | |
| 008 | 181219s2018 | |||||||||||000 ||eng| | |
| 009 | oai:prod.swepub.kib.ki.se:139700424 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1540492 URI |
| 024 | 7 | a https://doi.org/10.1186/s13058-018-1065-02 DOI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1397004242 URI |
| 040 | a (SwePub)umud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Frisk, Gabriellau Karolinska Institutet4 aut |
| 245 | 1 0 | a No association between low-dose aspirin use and breast cancer outcomes overall :b a Swedish population-based study |
| 264 | c 2018-11-20 | |
| 264 | 1 | b BioMed Central,c 2018 |
| 338 | a electronic2 rdacarrier | |
| 520 | a Background: Results from previous studies indicate that use of low-dose aspirin may improve breast cancer prognosis. We evaluated aspirin use and breast cancer outcomes in relation to clinical characteristics as well as dose and duration of aspirin use.Methods: We used information from the Regional Breast Cancer Quality-of-Care Registries in three Swedish regions to identify 21,414 women diagnosed with a first stage I-III breast cancer between 1 April 2006 and 31 December 2012. The cohort was further linked to nationwide registers to retrieve information about dispensing low-dose aspirin before and after breast cancer diagnosis, comorbidity and causes of death. In a separate analysis, we investigated time to breast cancer death among 621 women with stage IV disease at diagnosis. Associations were evaluated using a multivariable Cox proportional hazards model.Results: Among women with stage I-III breast cancer, 2660 (12.4%) used low-dose aspirin shortly before breast cancer diagnosis and 4091 (19.1%) were users during follow-up. Women were followed for a median of 3.8years after diagnosis. There was no association between aspirin use and breast cancer-specific death in multivariable analyses (use before diagnosis: hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.77-1.12; use after diagnosis: HR 1.00, 95% CI 0.74-1.37). Similarly, aspirin use was not associated with risk of first recurrence/metastases in a subgroup of stage I-III breast cancer patients (HR 0.97, 95% CI 0.86-1.10). However, in analyses stratified by stage, an inverse association between low-dose aspirin use after diagnosis and breast cancer death was found for women with stage I tumors (HR 0.53, 95% CI 0.29-0.96). Among women with stage IV disease at diagnosis, aspirin use was not associated with time to breast cancer death (HR 0.91, 95% CI 0.67-1.23).Conclusion: In this large population-based cohort study there was no evidence that low-dose aspirin use before or after breast cancer diagnosis is associated with a reduced risk of adverse outcomes overall in breast cancer. However, a potential benefit was noted among women with stage I tumors, warranting further investigation. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a Aspirin | |
| 653 | a Breast cancer | |
| 653 | a Sweden | |
| 653 | a Registers | |
| 700 | 1 | a Ekberg, Sarau Karolinska Institutet4 aut |
| 700 | 1 | a Lidbrink, Elisabet4 aut |
| 700 | 1 | a Eloranta, Sandrau Karolinska Institutet4 aut |
| 700 | 1 | a Sund, Malinu Umeå universitet,Kirurgi4 aut0 (Swepub:umu)masu0021 |
| 700 | 1 | a Fredriksson, Irmau Karolinska Institutet4 aut |
| 700 | 1 | a Lambe, Matsu Karolinska Institutet4 aut |
| 700 | 1 | a Smedby, Karin E.u Karolinska Institutet4 aut |
| 710 | 2 | a Karolinska Institutetb Kirurgi4 org |
| 773 | 0 | t Breast Cancer Researchd : BioMed Centralg 20q 20x 1465-5411x 1465-542X |
| 856 | 4 | u https://doi.org/10.1186/s13058-018-1065-0y Fulltext |
| 856 | 4 | u https://umu.diva-portal.org/smash/get/diva2:1272547/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 | u https://breast-cancer-research.biomedcentral.com/track/pdf/10.1186/s13058-018-1065-0 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-154049 |
| 856 | 4 8 | u https://doi.org/10.1186/s13058-018-1065-0 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:139700424 |
Hitta mer i SwePub
- Av författaren/redakt...
- Frisk, Gabriella
- Ekberg, Sara
- Lidbrink, Elisab ...
- Eloranta, Sandra
- Sund, Malin
- Fredriksson, Irm ...
- visa fler...
- Lambe, Mats
- Smedby, Karin E.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Breast Cancer Re ...
- Av lärosätet
- Umeå universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
